Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.

Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M.

Antimicrob Agents Chemother. 2015 May;59(5):2607-17. doi: 10.1128/AAC.04836-14.

2.

Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses.

Duan S, Govorkova EA, Bahl J, Zaraket H, Baranovich T, Seiler P, Prevost K, Webster RG, Webby RJ.

Nat Commun. 2014 Oct 9;5:5029. doi: 10.1038/ncomms6029.

3.

Genome rearrangement of influenza virus for anti-viral drug screening.

Sutton TC, Obadan A, Lavigne J, Chen H, Li W, Perez DR.

Virus Res. 2014 Aug 30;189:14-23. doi: 10.1016/j.virusres.2014.05.003.

4.

Airborne transmission of highly pathogenic H7N1 influenza virus in ferrets.

Sutton TC, Finch C, Shao H, Angel M, Chen H, Capua I, Cattoli G, Monne I, Perez DR.

J Virol. 2014 Jun;88(12):6623-35. doi: 10.1128/JVI.02765-13.

5.

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.

Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV.

Influenza Other Respir Viruses. 2014 Mar;8(2):258-65. doi: 10.1111/irv.12215.

6.

Molecular evolution of the hemagglutinin and neuraminidase genes of pandemic (H1N1) 2009 influenza viruses in Sendai, Japan, during 2009-2011.

Khandaker I, Suzuki A, Kamigaki T, Tohma K, Odagiri T, Okada T, Ohno A, Otani K, Sawayama R, Kawamura K, Okamoto M, Oshitani H.

Virus Genes. 2013 Sep 29. [Epub ahead of print]

7.

Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan.

Liu CH, Wang JL, Su CP, Chuang JH, Chang CH, Lai MS.

BMC Public Health. 2013 Jul 12;13:646. doi: 10.1186/1471-2458-13-646.

8.

Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.

Takashita E, Fujisaki S, Kishida N, Xu H, Imai M, Tashiro M, Odagiri T; Influenza Virus Surveillance Group of Japan..

Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132.

9.

Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established.

Dimmock NJ, Dove BK, Scott PD, Meng B, Taylor I, Cheung L, Hallis B, Marriott AC, Carroll MW, Easton AJ.

PLoS One. 2012;7(12):e49394. doi: 10.1371/journal.pone.0049394.

10.

Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.

Dimmock NJ, Dove BK, Meng B, Scott PD, Taylor I, Cheung L, Hallis B, Marriott AC, Carroll MW, Easton AJ.

Antiviral Res. 2012 Dec;96(3):376-85. doi: 10.1016/j.antiviral.2012.09.017.

11.

Amino acids transitioning of 2009 H1N1pdm in Taiwan from 2009 to 2011.

Chen GW, Tsao KC, Huang CG, Gong YN, Chang SC, Liu YC, Wu HH, Yang SL, Lin TY, Huang YC, Shih SR.

PLoS One. 2012;7(9):e45946. doi: 10.1371/journal.pone.0045946.

12.

Structural basis for proton conduction and inhibition by the influenza M2 protein.

Hong M, DeGrado WF.

Protein Sci. 2012 Nov;21(11):1620-33. doi: 10.1002/pro.2158. Review.

13.

Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan.

Dapat IC, Dapat C, Baranovich T, Suzuki Y, Kondo H, Shobugawa Y, Saito R, Suzuki H; Japanese Influenza Collaborative Study Group..

PLoS One. 2012;7(6):e36455. doi: 10.1371/journal.pone.0036455.

14.

The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Wu WL, Lau SY, Chen Y, Wang G, Mok BW, Wen X, Wang P, Song W, Lin T, Chan KH, Yuen KY, Chen H.

Antiviral Res. 2012 Jan;93(1):144-53. doi: 10.1016/j.antiviral.2011.11.006.

15.

In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001.

16.

Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand.

Payungporn S, Poomipak W, Makkoch J, Rianthavorn P, Theamboonlers A, Poovorawan Y.

J Virol Methods. 2011 Nov;177(2):133-9. doi: 10.1016/j.jviromet.2011.07.008.

17.

Structural basis for the function and inhibition of an influenza virus proton channel.

Stouffer AL, Acharya R, Salom D, Levine AS, Di Costanzo L, Soto CS, Tereshko V, Nanda V, Stayrook S, DeGrado WF.

Nature. 2008 Jan 31;451(7178):596-9. doi: 10.1038/nature06528. Erratum in: Nature. 2008 Mar 20;452(7185):380.

Items per page

Supplemental Content

Support Center